Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Xilio Development Inc (XLO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/06/2025: XLO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -45.36% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.26M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 7405353 | Beta -0.34 | 52 Weeks Range 0.63 - 1.70 | Updated Date 04/2/2025 |
52 Weeks Range 0.63 - 1.70 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date 2025-03-11 | When - | Estimate -0.22 | Actual -0.2 |
Profitability
Profit Margin - | Operating Margin (TTM) -790.55% |
Management Effectiveness
Return on Assets (TTM) -56.48% | Return on Equity (TTM) -214.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -11891099 | Price to Sales(TTM) 5.56 |
Enterprise Value -11891099 | Price to Sales(TTM) 5.56 | ||
Enterprise Value to Revenue 0.05 | Enterprise Value to EBITDA -0.11 | Shares Outstanding 51773700 | Shares Floating 21998135 |
Shares Outstanding 51773700 | Shares Floating 21998135 | ||
Percent Insiders 28.17 | Percent Institutions 45.72 |
Analyst Ratings
Rating 4.33 | Target Price 4.5 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Xilio Development Inc
Company Overview
History and Background
Xilio Therapeutics is a biopharmaceutical company founded in 2016 and headquartered in Waltham, Massachusetts. They focus on developing tumor-selective immuno-oncology therapies for cancer. The company has advanced multiple programs into clinical development.
Core Business Areas
- Immuno-Oncology: Developing tumor-selective immuno-oncology therapies designed to unleash the power of the immune system to eradicate cancer.
Leadership and Structure
Xilio Therapeutics is led by its CEO, Dr. Salim Yazji. The company has a Board of Directors and a management team with expertise in drug development, immunology, and oncology.
Top Products and Market Share
Key Offerings
- XTX101: A tumor-selective anti-CTLA-4 antibody. It is currently in clinical trials. Market share is not yet applicable as it is not approved. Competitors include approved CTLA-4 inhibitors like Yervoy (ipilimumab) from Bristol Myers Squibb, and other companies developing novel CTLA-4 inhibitors.
- XTX202: An IL-2 therapy designed to active T Cells in the tumor microenvironment. It is currently in clinical trials. Market share is not yet applicable as it is not approved. Competitors include Sanofi (SAR) who are developing an IL-2 therapy, Keytruda(MRK) and Opdivo (BMY)
Market Dynamics
Industry Overview
The immuno-oncology market is a rapidly growing sector within the pharmaceutical industry, focused on harnessing the body's immune system to fight cancer. It is characterized by intense competition, high innovation, and significant investment.
Positioning
Xilio is positioned as an innovator in the immuno-oncology space, focusing on tumor-selective therapies to reduce systemic toxicity. This approach provides a competitive advantage by potentially offering improved efficacy and safety compared to traditional immuno-oncology agents.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of dollars in the coming years. Xilio aims to capture a significant portion of this market through its innovative tumor-selective therapies. It is early for them to position in the market because it does not have any approved drugs yet.
Upturn SWOT Analysis
Strengths
- Novel tumor-selective technology platform
- Experienced management team
- Clinical-stage pipeline
- Strong intellectual property position
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- Dependence on successful clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new cancer targets
- Positive clinical trial data leading to regulatory approval
- Acquisition by a larger player
Threats
- Competition from established immuno-oncology therapies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- AZN
- LLY
Competitive Landscape
Xilio's competitive advantage lies in its tumor-selective technology. However, it faces competition from larger pharmaceutical companies with established immuno-oncology therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Xilio's growth has been focused on advancing its pipeline through preclinical and clinical development.
Future Projections: Future growth depends on the success of its clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives include advancing XTX101 and XTX202 through clinical trials and exploring new targets for its tumor-selective technology.
Summary
Xilio Therapeutics is a development-stage biopharmaceutical company with a promising tumor-selective immuno-oncology platform. While the company faces risks inherent in drug development, its innovative approach and experienced management team position it for potential growth. It will need to secure funding to further the advancement of its clinical trials. Xilio should focus on good results in its clinical trials and partnerships.
Similar Companies
ADAP
Adaptimmune Therapeutics Plc
ADAP
Adaptimmune Therapeutics Plc
AGEN
Agenus Inc
AGEN
Agenus Inc
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share figures are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xilio Development Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-10-22 | President, CEO & Director Dr. Rene Russo BCPS, Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://xiliotx.com |
Full time employees 64 | Website https://xiliotx.com | ||
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.